TOP TEN perturbations for 39407_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39407_at
Selected probe(set): 205574_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39407_at (205574_x_at) across 6674 perturbations tested by GENEVESTIGATOR:

pancreatic islet study 3 (re-differentiated; PPRF; 2d) / normal pancreatic islet sample

Relative Expression (log2-ratio):2.9979563
Number of Samples:2 / 7
Experimental pancreatic islet study 3 (re-differentiated; PPRF; 2d)
Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 2 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0ug/ml.
Control normal pancreatic islet sample
Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation.

pancreatic islet study 3 (re-differentiated; PPRF; 4d) / normal pancreatic islet sample

Relative Expression (log2-ratio):2.963194
Number of Samples:2 / 7
Experimental pancreatic islet study 3 (re-differentiated; PPRF; 4d)
Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 4 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0ug/ml.
Control normal pancreatic islet sample
Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation.

breast cancer study 40 (metastase; ovary) / ovarian tumor study 28 (carcinosarcoma)

Relative Expression (log2-ratio):-2.95934
Number of Samples:44 / 2
Experimental breast cancer study 40 (metastase; ovary)
Metastatic tumor tissue obtained from the ovary of female patients with primary breast cancer.
Control ovarian tumor study 28 (carcinosarcoma)
Primary tumor tissue sample obtained from the ovary of female patients with carcinosarcoma.

pancreatic islet study 3 (re-differentiated; PPRF; 6d) / normal pancreatic islet sample

Relative Expression (log2-ratio):2.852993
Number of Samples:2 / 7
Experimental pancreatic islet study 3 (re-differentiated; PPRF; 6d)
Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 6 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0 ug/ml.
Control normal pancreatic islet sample
Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation.

retina pigment epithelium study 2 (fetal) / retina pigment epithelium study 1 (fetal)

Relative Expression (log2-ratio):2.789507
Number of Samples:12 / 6
Experimental retina pigment epithelium study 2 (fetal)
Human cultured fetal retina pigment epithelium samples obtained at gestation age between week 16-18.
Control retina pigment epithelium study 1 (fetal)
Human native fetal retina pigment epithelium samples obtained at gestation age between week 16-18.

stem cell differentiation study 41 (T3pi) / stem cell differentiation study 41 (hES-T3 EB)

Relative Expression (log2-ratio):2.4712715
Number of Samples:2 / 2
Experimental stem cell differentiation study 41 (T3pi)
Sample of pancreatic islet-like cell clusters differentiated from human embryonic stem cells T3 with female karyotype.
Control stem cell differentiation study 41 (hES-T3 EB)
Sample of embryonic bodies (EB) differentiated from human embryonic stem cells T3 with female karyotype.

pancreatic islet study 3 (re-differentiated; PPRF; 8d) / normal pancreatic islet sample

Relative Expression (log2-ratio):2.4678164
Number of Samples:2 / 7
Experimental pancreatic islet study 3 (re-differentiated; PPRF; 8d)
Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 8 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0 ug/ml.
Control normal pancreatic islet sample
Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation.

pancreatic islet study 3 (expanded; NIH) / normal pancreatic islet sample

Relative Expression (log2-ratio):2.388402
Number of Samples:3 / 7
Experimental pancreatic islet study 3 (expanded; NIH)
Pancreatic islet cells were expanded according to National Institutes of Health (NIH) protocol for 10 weeks. Expansion phase: 2,000 islet equivalents enriched by retention on a 40-μm filter were seeded onto tissue culture–treated dishes in CMRL-1066 medium containing 2 mmol/l l-glutamine and 10% fetal bovine serum.
Control normal pancreatic islet sample
Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation.

ovarian tumor study 28 (carcinosarcoma) / ovarian tumor study 28 (adenocarcinoma)

Relative Expression (log2-ratio):2.3600597
Number of Samples:2 / 3
Experimental ovarian tumor study 28 (carcinosarcoma)
Primary tumor tissue sample obtained from the ovary of female patients with carcinosarcoma.
Control ovarian tumor study 28 (adenocarcinoma)
Primary tumor tissue sample obtained from the ovary of female patients with adenocarcinoma.

expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary) / expO lung cancer study 1 (adenosquamous carcinoma; primary)

Relative Expression (log2-ratio):-2.3209572
Number of Samples:2 / 3
Experimental expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary)
Primary tumor tissue samples obtained from the lung of patients with papillary adenocarcinoma (NOS).
Control expO lung cancer study 1 (adenosquamous carcinoma; primary)
Primary tumor tissue samples obtained from the lung of patients with adenosquamous carcinoma.